GlassScriptPhysician profile
Richard L Griffith
NPI 1528050838
$4,412.88
in general payments reported to CMS, 2019-2025
41 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $1,006 · 2021: $667 · 2022: $728 · 2023: $644 · 2024: $422 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Consulting Fee: $17.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.27 |
| Consulting Fee | $17.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $640.18 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $436.36 | 2019-2025 | |
| Pfizer INC. | $355.83 | 2020-2025 | |
| Antares Pharma, INC. | $269.76 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Grifols USA, LLC | $217.46 | 2020-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $213.75 | 2020-2024 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $200.25 | 2019-2024 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.78 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $167.69 | 2019-2021 | |
| Octapharma USA, INC. | $129.84 | 2020-2021 | |
| Novo Nordisk INC | $129.55 | 2019-2023 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $127.11 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $120.93 | 2020-2023 | Belsomra |
| Lilly USA, LLC | $119.57 | 2020-2025 | Kisunla, Zepbound, Mounjaro |
| Xeris Pharmaceuticals, INC. | $83.43 | 2021-2023 | Gvoke Hypopen |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.